Brand-to-brand nonmedical switching among interleukin-17 inhibitors or other biologics: Implications of a formulary change
Following the formulary change, more than 25% of patients exposed to the change experienced treatment discontinuation, nearly double the rate than those not exposed. This unfavorable finding, along with higher rates of nonadherence and subsequent switching, warrants careful monitoring of similar policy changes.
Authors
- Yifei Liu (ORCID: https://orcid.org/0000-0003-3597-8706)
- Yi Peng (ORCID: https://orcid.org/0000-0003-1593-8336)
- Beverly Johns
- Cynthia Holmes
- A. Mark Fendrick (ORCID: https://orcid.org/0000-0002-7734-6742)
- Manish Mittal
Institutions
- University of Michigan (US)
- AbbVie (United States) (US)
- University of Missouri–Kansas City (US)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2025-04-23
- DOI
- https://doi.org/10.18553/jmcp.2025.24317
- Citations
- 1
- Primary Topic
- Pharmaceutical industry and healthcare
- Type
- article
- Field-Weighted Citation Impact
- 1.56